Evidence tiers — what each class of evidence actually proves

Extract vs synthetic (the central distinction)

The extract-vs-synthetic gap. Nearly all human outcome data (including the 266-patient elderly cohort with reported 2–4× mortality reduction, 6–8-year follow-up) was obtained on biological extracts — Epithalamin, Thymalin — multi-peptide mixtures with no defined composition. The compounds sold globally today are defined synthetic fragments (Epitalon AEDG, Vilon KE, Prostamax KEDP…). No head-to-head extract-vs-synthetic trial exists for any pair. The 2017 Kopylov paper identifying AEDG within the pineal complex is the only direct lineage bridge. Evidence for the extract does not transfer to the synthetic; treat them as different drugs until proven otherwise.

Tier	What it is	Can you trust it? / What can it prove?
EXTRACT	Biological extract from animal tissue — undefined multi-peptide mixture (Epithalamin, Thymalin, Cortexin, Retinalamin). Russian-registered drugs since the Soviet era.	Single-institution observational data. No randomization, no placebo control, no blinding. The 266-patient mortality cohort (published twice by the same two authors, 2002 + 2003 = ONE study) reports 2–4× mortality reduction with no per-arm n, no CIs, no p-values. Proves signal worth testing; proves nothing by Western standards.
SYNTHETIC	Defined 2–4 amino-acid peptide from solid-phase synthesis (Epitalon AEDG, Vilon KE, Prostamax KEDP…). What every vendor sells.	In-vitro mechanistic data only — mainly from Khavinson's own institute. Entire independent Western mechanistic confirmation for Epitalon = two 2025 studies (Al-Dulaimi PMID 40908429; Gatta et al.). Pinealon: one independent Western screen, essentially null. Zero human RCTs of any Khavinson synthetic anywhere.
EXTRACT→SYN	Derivation paper: identifies the active fragment within the extract, motivating the synthetic (e.g. Kopylov 2017 — AEDG identified within pineal peptide complex).	Establishes lineage, not equivalence. In-vitro effects at similar concentrations ≠ same clinical effect in humans.
untagged	Publication title gives no extract/synthetic signal.	Unclassified — read before citing.

The FDA ruling (July 24, 2026)

At the FDA Pharmacy Compounding Advisory Committee, FDA staff recommended against listing epitalon, stating it is "not well-characterized", there is "no clinical data to support safety of epitalon when used in humans", and that "epitalon has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer." The committee voted 7–4–1 to recommend listing anyway, over FDA objection. This is the first formal Western regulatory review — FDA skepticism is on the public record.

Independent (non-Khavinson) studies — complete list

Epitalon (AEDG) — Independent study — Biogerontology, 2025, PMID 40908429 in-vitro
Brunel University London · Biogerontology · PMID 40908429

Result: Independent Western lab confirmed telomere extension in normal human cells via hTERT upregulation. Also found ALT (Alternative Lengthening of Telomeres) activation in breast cancer cell lines but NOT normal cells — a mechanism distinction absent from all vendor marketing.

Significance: First independent non-Russian confirmation of Epitalon's core mechanism. Also opened the cancer-cell ALT question.

Epitalon — Gatta et al. 2025, retinal wound healing, with Khavinson Institute co-authorship in-vitro

Result:

Significance: Second Western mechanistic confirmation — restored wound healing in retinal cells under high glucose. Partially independent (Khavinson co-author).

Thymosin alpha-1 (adjacent class) — TESTS trial, BMJ 2025, Phase 3, n=1106, sepsis mortality independent

Result: NULL. 23.4% vs 24.1% 28-day mortality, HR 0.99.

Significance: Largest properly blinded trial of any thymic peptide. Effect seen in smaller trials evaporated at scale. Cautionary parallel for Thymalin claims.

Pinealon (EDR) — 2026 independent Western mouse functional screen independent

Result: Near-null. Safe but no significant geroprotective effect vs positive controls, only non-significant cognitive trend. Positive controls performed as expected.

Significance: First comprehensive functional screen of a Khavinson peptide by an independent Western lab. Returned essentially nothing.

Epitalon — FDA Pharmacy Compounding Advisory Committee, July 24 2026 independent

Result: FDA staff recommended AGAINST listing. Quote: 'not well-characterized', 'no clinical data to support safety of epitalon when used in humans', 'epitalon has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer.' Committee voted 7-4-1 to recommend listing anyway, over FDA objection.

Significance: First formal Western regulatory review. FDA skepticism on the public record.

Cancer-safety question

Epitalon 2025 (Brunel): telomerase activation confirmed in normal cells, plus activation of ALT (Alternative Lengthening of Telomeres) in breast cancer cell lines — but not normal cells. Pre-cancerous cell behavior is untested in vivo. FDA position: see above.

What real research would look like

Randomized, placebo-controlled, blinded trial of the synthetic compound — the only class that can settle the sell-what-you-tested problem.
Objective endpoints per compound (see measurement protocols), pre-registered, with per-arm n and CIs.
Head-to-head extract vs synthetic for at least one pair (Epitalon vs Epithalamin is the obvious first) — absent entirely.
Independent (non-Russian-institute) labs — currently the 2025/2026 in-vitro papers plus one null mouse screen are the whole non-Khavinson record.

The critical unresolved question: the 266-patient mortality study used extracts. The compounds sold are synthetics. No comparative trial exists. Evidence for one does not transfer to the other.